Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer-BioNTech Covid-19 vaccine gets Canada approval for adolescents
Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years. This Covid-19
Pfizer Canada and BioNTech have received Interim Order authorisation from Health Canada for the use of their Covid-19 vaccine in adolescents aged 12 to 15 years. This Covid-19
ViiV Healthcare has initiated a rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for long-acting cabotegravir to prevent human immunodeficiency
Specialty life sciences company Revive Therapeutics has signed a research agreement with University of California, San Francisco (UCSF) to study Bucillamine as a potential treatment for severe Covid-19.
World Health Organization (WHO) has granted emergency use listing (EUL) for Moderna’s Covid-19 vaccine to prevent the infection in people aged 18 years and above. The Covid-19 Vaccine
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China. Maralixibat is a minimally absorbed, orally
Pharmaceutical company Pfizer has acquired a privately held company Amplyx Pharmaceuticals for an undisclosed amount. Amplyx is developing treatment for life-threatening diseases caused due to failing immune system.
Merck, called as MSD outside the US and Canada, has signed voluntary licensing agreements with five Indian generic drug makers to expand access to Molnupiravir, an experimental oral
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended conditional marketing authorisation for AstraZeneca and Merck’s selumetinib to treat paediatric patients aged
A study, conducted by The Institute of Cancer Research, London (ICR) and Paris-based cancer research institute Gustave Roussy, identified that drugs known as PARP inhibitors kill cancer cells
Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing. The strategic collaboration and research and licensing agreement